The company's proprietary technology platform enables the precise modification of the genome to target specific diseases and make a range of changes, from small to larger DNA fragments. By expanding the programmability of recombinases, Seamless Therapeutics aims to develop a pipeline of disease-modifying therapies for a wide range of conditions. Founded in 2022 and based in Dresden, Germany, the company is focused on restoring health in patients with severe conditions through safe and precise gene editing techniques.